Cancer Research

St. Jude Children’s Research Hospital Affiliate

The following studies for care of children with cancer are available through the St. Jude Children’s Research Hospital:

AML08: A Phase III Randomized Trial of Clofarabine Plus Cytarabine Versus Conventional Induction Therapy and A Phase II Study of Natural Killer Cell Transplantation in Patients with Newly Diagnosed Acute Myeloid Leukemia

IPACTR: International Pediatric Adrenocortical Tumor Registry

SJYCO07: Risk-Adapted Therapy for Children Less than 3 Years of Age with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma

Total Therapy Study XVI for Newly Diagnosed Patients with Acute Lymphoblastic Leukemia

HOD08: Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma

SJBC3: Mature B-Cell Lymphoma and Leukemia Study III

ETHEL-A Double-Blind, Randomized, Placebo-controlled Trial of Ethanol Lock Therapy for Treatment and Secondary Prophylaxis of Central Line Associated Bloodstream Infection (CLABSI) in Children and Adolescents

ANGIO- Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia

 

Children’s Oncology Group

The following studies sponsored through Children’s Oncology Group are available for enrollment:

AREN03B2: Renal Tumors Classification, Biology, and Banking Study

ANHL04B1: Rare and Cutaneous Non-Hodgkin Lymphoma Registry

ARST0531: Randomized Study of Vincristine, Dactinomycin and Cyclophosphomade (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate

*ANBL00P3: A Phase III Randomized Trial of Intravenous Gamma globulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone   (Pedro de Alarcon, MD, Principle Investigator)

ACNS02B3: A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens

ACNS0331: A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Meulloblastoma: A Phase III Double Randomized Trial

ALTE03N1: Key Adverse Events after Childhood Cancer

COG ACCRN07: Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)

D9902: A COG Soft Tissue Sarcoma Biology and Tissue Banking Protocol

ABTR04B1: Establishing Continuous Cell Lines and Xenografts from Pediatric Cancers for Biological and Pre-Clinical Therapeutic Studies

ABTR01B1 – A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Rare Pediatric Tumors

COG AREN0532: Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor

ANBL00B1: Neuroblastoma Biology Studies Protocol

AREN0533: Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumor

AREN0321: Treatment of High Risk Renal Tumors

AEWS07B1: A COG Study for Collecting and Banking Ewing Sarcoma Specimens

ARAR0332: Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy

AOST06B1: A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens

AHOD04B1: Hodgkin Disease (HD) Banking Study

AHEP0731: Treatment of Children with All Stages of Hepatoblastoma

ARST08P1: A Pilot Study to Evaluate Novel Agent Cixutumumab (IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC #742460) in Combination With Intensive Multi-Agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma

ALTE07C1: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer

AREN0534: Treatment for Patients With Multicentric or Bilaterally-Predisposed Unilateral Wilms Tumor

AEWS1031: A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastaic Ewing Sarcoma

ANBL0032: Phase III Randomized Study of Chimeric Antibody 14, 18 (Ch 14, 18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue

ACNS1021: A Phase II Study of Sunitinib (NSC#736511, IND #74019) in Recurrent, Refractory or Progressive High Grade Giloma and Ependymoma tumors in Pediatric and Young Adult Patients

ACNS0822: A Randomized Phase II/III Study of Vorinostat (IND #71976) and Local Irradiation or Temozolomide and Local Irradiation or Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND #7921) and Temozolomide in Newly Diagnosed High Grade Glioma